Integrated Pharmacy Research and Practice (Jun 2024)
Warfarin and Polypharmacy Challenges in Sudan: Drug Interactions in Patient Cohort
Abstract
Ahmed AA Omer,1 Abdal Mahmoud Elsiddig,2 Imad M Taj1 1Department of Pharmacology Faculty of Pharmacy, University of Gezira, Wad Medani, Gezira State, 21111, Sudan; 2Medani Heart Centre, Wad Medani, Gezira State, 550, SudanCorrespondence: Ahmed AA Omer, Department of Pharmacology Faculty of Pharmacy, University of Gezira, Wad Medani, Gezira State, 21111, Sudan, Tel +249912234128, Email [email protected]: Warfarin plays an important role in anticoagulation therapy despite the availability of the newest oral anticoagulants, and achieving optimal anticoagulation is challenging due to its narrow therapeutic range and variable dose. This study aimed to highlight polypharmacy and drug interactions in patients receiving warfarin therapy at Medani Heart Centre, Sudan.Methods: This retrospective hospital-based study was conducted from May 2017 to October 2018. Each concurrent medication prescribed for 104 patients was collected and checked for drug-drug interactions using Medscape Reference-Drug Interaction Checker. The data were analysed by using SPSS 20, and descriptive statistics were used.Results: The results revealed that 95.2% of patients had more than three medications in their profile, (3– 5), (6– 9) and more than 10 medications were prescribed for 40.4%, 44.2% and 10.6% of patients, respectively. A total of 93.3% of patients had drug-drug interactions, as follows: (1– 5), (6– 10), (11– 15), (16– 20) and more than 20 drug-drug interactions were found in 31.7%, 32.7%, 19.2%, 5.8% and 3.8% of patients, respectively. A total of 178 warfarin-drug interactions were identified in 88.5% of the patients. The INR ranged between 2 and 2.99 in 13.4% of patients, and INR values below 2 and above 5 were found in 44.2% and 21.2% of patients, respectively. Analgesics (n=54; 30.3%), cardiovascular drugs (n=51; 28.6%), and anticoagulants (n=46; 25.8%) were the most common drug classes that interact with warfarin. Significant and serious types of interactions with warfarin were found in 51% and 37.5% of patients, respectively.Conclusion: This study highlights the complexity of managing warfarin therapy amid prevalent polypharmacy. A substantial majority of patients experienced multiple drug interactions. The identification of significant and serious interactions emphasizes the need for vigilant management strategies, including improved communication among healthcare professionals and targeted education for both providers and patients, to enhance the safety and efficacy of warfarin therapy.Keywords: drug-drug interaction, INR, patient, poly pharmacy, warfarin
